Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020206549 - METHODS, COMPOSITIONS AND KITS FOR THE ASSESSMENT OF MILD COGNITIVE IMPAIRMENT

Publication Number WO/2020/206549
Publication Date 15.10.2020
International Application No. PCT/CA2020/050475
International Filing Date 09.04.2020
IPC
G01N 33/48 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
G01N 33/53 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Applicants
  • INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE [CA]/[CA]
Inventors
  • RAMASSAMY, Charles
  • PERROTTE, Morgane
  • HADDAD, Mohamed
Agents
  • LAVERY, DE BILLY, LLP
Priority Data
62/831,77210.04.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS, COMPOSITIONS AND KITS FOR THE ASSESSMENT OF MILD COGNITIVE IMPAIRMENT
(FR) PROCÉDÉS, COMPOSITIONS ET KITS POUR L'ÉVALUATION DES TROUBLES COGNITIFS LÉGERS
Abstract
(EN)
Methods, compositions and kits for the assessment and management of mild cognitive impairment (MCI) and early stage Alzheimer's disease (AD), and to monitor changes in cognitive functions in subjects over time, are described. The assessment for MCI and early stage AD is based on the level of BDNF, NSE, S100B, PGRN and/or the PGRN/BDNF ratio, in plasma-derived extracellular vesicles (EVs) from a subject.
(FR)
L'invention concerne des procédés, des compositions et des kits pour l'évaluation et la gestion d'un trouble cognitive léger (MCI) et d'un stade précoce de la maladie d'Alzheimer (AD), et pour surveiller des changements de fonctions cognitives chez des sujets au cours du temps. L'évaluation d'un MCI et d'un stade précoce de l'AD est basée sur le niveau de BDNF, NSE, CIB, PGRN et/ou le rapport PGRN/BDNF, dans des vésicules extracellulaires dérivées du plasma (EVs) provenant d'un sujet.
Latest bibliographic data on file with the International Bureau